Fate Therapeutics (F6T) Price & Analysis

Compare

1 Followers

F6T Stock Chart & Stats

€1.15

€0.07(3.83%)

At close: Jan 08 4:00 PM EST

€1.15

€0.07(3.83%)

Day’s Range― - ―

52-Week Range€0.60 - €1.49

Previous CloseN/A

Volume185.00

Average Volume (3M)136.00

Market Cap

€133.07M

Enterprise Value€185.85M

Total Cash (Recent Filing)€203.66M

Total Debt (Recent Filing)€77.85M

Price to Earnings (P/E)―

Beta0.62

Next Earnings

May 06, 2026

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.23

Shares Outstanding116,263,460

10 Day Avg. Volume0

30 Day Avg. Volume136

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.56

Price to Sales (P/S)17.56

P/FCF Ratio-1.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€3.30

Price Target Upside186.60% Upside

Rating ConsensusHold

Number of Analyst Covering5

EPS Forecast (FY)-0.96

Revenue Forecast (FY)€5.01M

Bulls Say, Bears Say

Bulls Say

Early Clinical Activity Across Autoimmune IndicationsEarly clinical signals, including measurable improvement in a treated systemic sclerosis patient across several clinical measures, suggest the therapy may have activity across multiple autoimmune disorders and could broaden its market potential.

Regulatory Fast-track And Pivotal PathA regulatory fast-track designation supports plans for a pivotal trial in systemic lupus erythematosus and lupus-related kidney disease, potentially shortening the pathway to approval if confirmatory data are achieved.

Trial Enrollment ExpansionEnrollment in FT819 trials is expanding across multiple international sites, including additional European centers, which can speed data collection and support more robust clinical readouts.

Bears Say

Investor Risk From Data VariabilityLimited patient numbers make early efficacy and safety signals vulnerable to variability, raising the risk of significant share-price volatility if subsequent results do not confirm initial findings.

Limited Patient DataThe program has treated only a small number of patients, which limits confidence in conclusions about safety and effectiveness until larger datasets are available.

Regulatory Uncertainty From Small CohortsSmall trial cohorts increase regulatory uncertainty because authorities typically expect broader safety and efficacy evidence before granting approval for a novel cell therapy.

Fate Therapeutics News

Fate Therapeutics reports Q4 EPS (77c), consensus (27c)

Reports Q4 revenue $1.369M, consensus $1.2M. “I am extremely proud of the progress the Fate team delivered in...

10d ago

FATE

Maintaining a Hold on Fate Therapeutics as FT819’s Clinical and Commercial Profile Remains Unclear

Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating yesterday. Gil...

9d ago

FATE

Fate Therapeutics presents updated Phase 1 data of FT819

Fate Therapeutics (FATE) presented updated clinical data from its ongoing Phase 1 trial evaluating its FT819 off-the-shelf iPSC-derived...

3M ago

FATE

Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts

Fate Therapeutics Inc ( ($FATE) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

FATE

Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks

Fate Therapeutics Inc (FATE) has disclosed a new risk, in the Environmental / Social category. Fate Therapeutics Inc....

4M ago

FATE

Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment

TD Cowen analyst Tara Bancroft has maintained their neutral stance on FATE stock, giving a Hold rating on...

4M ago

FATE

Fate Therapeutics reports Q3 EPS (27c), consensus (28c)

Reports Q3 revenue $1.741M, consensus $1.68M. “The potentially transformative impact of FT819 in lupus is at an inflection...

4M ago

FATE

Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Robert Burns upgraded Fate Therapeutics (FATE) to Buy from Neutral with a $5 price target...

4M ago

FATE

Is FATE a Buy, Before Earnings?

Fate Therapeutics Inc (FATE) is scheduled to report 3rd quarter earnings on 10/30/2025. Regarding Q3 estimates, Wall Street...

4M ago

FATE

Fate Therapeutics Advances CAR T-Cell Therapy with New Clinical Study

Fate Therapeutics Inc (($FATE)) announced an update on their ongoing clinical study. Fate Therapeutics Inc. is conducting a...

4M ago

FATE

Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment

Fate Therapeutics Inc (($FATE)) announced an update on their ongoing clinical study. Study Overview: Fate Therapeutics Inc. is...

4M ago

FATE

Fate Therapeutics’ Innovative CAR T-Cell Therapy Study: A Potential Game-Changer in Cancer Treatment

Fate Therapeutics Inc (($FATE)) announced an update on their ongoing clinical study. Fate Therapeutics Inc. is conducting a...

4M ago

FATE

Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7

As previously reported, Wedbush analyst Martin Fan upgraded Fate Therapeutics (FATE) to Outperform from Neutral with a price...

4M ago

FATE

Fate Therapeutics Reports Promising Phase 1 Trial Results

The latest update is out from Fate Therapeutics ( ($FATE) ). On October 26, 2025, Fate Therapeutics announced...

4M ago

FATE

F6T FAQ

What was Fate Therapeutics Inc’s price range in the past 12 months?

Fate Therapeutics Inc lowest stock price was €0.60 and its highest was €1.49 in the past 12 months.

What is Fate Therapeutics Inc’s market cap?

Fate Therapeutics Inc’s market cap is €133.07M.

When is Fate Therapeutics Inc’s upcoming earnings report date?

Fate Therapeutics Inc’s upcoming earnings report date is May 06, 2026 which is in 59 days.

How were Fate Therapeutics Inc’s earnings last quarter?

Fate Therapeutics Inc released its earnings results on Feb 26, 2026. The company reported -€0.231 earnings per share for the quarter, the consensus estimate of -€0.231 by €0.

Is Fate Therapeutics Inc overvalued?

According to Wall Street analysts Fate Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fate Therapeutics Inc pay dividends?

Fate Therapeutics Inc does not currently pay dividends.

What is Fate Therapeutics Inc’s EPS estimate?

Fate Therapeutics Inc’s EPS estimate is -0.24.

How many shares outstanding does Fate Therapeutics Inc have?

Fate Therapeutics Inc has 116,263,460 shares outstanding.

What happened to Fate Therapeutics Inc’s price movement after its last earnings report?

Fate Therapeutics Inc reported an EPS of -€0.231 in its last earnings report, expectations of -€0.231. Following the earnings report the stock price went down -9.125%.

Which hedge fund is a major shareholder of Fate Therapeutics Inc?

Currently, no hedge funds are holding shares in DE:F6T

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Fate Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-51.84%

Trailing 12-Months

Asset Growth

-27.63%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fate Therapeutics (F6T) Earnings & Revenues

Historic Earnings Reports

F6T Stock 12 Month Forecast

Average Price Target

€3.30

▲(186.60% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","3":"€3","5":"€5","7":"€7","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.02385273,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€6.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.2959079937,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€3.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.72110078,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.72</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.178,1.5507579023076923,1.9235158046153846,2.2962737069230768,2.6690316092307693,3.0417895115384614,3.4145474138461536,3.787305316153846,4.160063218461538,4.53282112076923,4.905579023076923,5.2783369253846155,5.651094827692307,{"y":6.02385273,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.178,1.3409159995153845,1.5038319990307691,1.6667479985461537,1.8296639980615383,1.992579997576923,2.1554959970923075,2.3184119966076926,2.4813279961230768,2.644243995638462,2.807159995153846,2.970075994669231,3.1329919941846156,{"y":3.2959079937,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.178,1.219776983076923,1.2615539661538462,1.3033309492307692,1.3451079323076922,1.3868849153846154,1.4286618984615385,1.4704388815384615,1.5122158646153845,1.5539928476923077,1.5957698307692307,1.637546813846154,1.679323796923077,{"y":1.72110078,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.037,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.715,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.005,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.023,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.917,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.927,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.895,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.032,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.158,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.933,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.817,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.937,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.178,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >